Board of Directors

William Wyman (Chairman)

Bill Wyman William W. Wyman began his career at the management consulting firm Booz Allen and Hamilton. After working for the firm in New York, Duesseldorf Germany, Athens Greece, and Dallas Texas, he returned to New York to become the President of the Management Consulting Group, a member of the executive committee, and a member of the Board of Directors. Subsequently, Mr. Wyman co-founded the management consulting firm, Oliver Wyman & Co. Now part of Marsh & McLennan, the firm employs nearly 3,000 professionals in 25 countries.

Mr. Wyman has served as a director/advisor to more than a dozen public and private companies, including Donaldson, Lufkin and Jenrette, and a number of smaller technology companies. He also has served as an advisor to several private equity partnerships.

Mr. Wyman received his BA from Colgate University, and his MBA from the Harvard Business School. He resides in Hanover, NH.

William Copeland

Mr. Copeland was a founding partner of Vinik Asset Management, a Boston Massachusetts hedge firm, where he was a capital market analyst and senior portfolio strategist for 17 years. Prior to this, he spent 12 years at Fidelity Investments where he was a senior technical market analyst serving both the equity and fixed income divisions of the management company.

Mr. Copeland worked at The Boston Company where he developed quantitative valuation models for different phases of the business cycle and contributed to a monthly capital market outlook publication.

Mr. Copeland received his Bachelor of Arts degree from Union College and his MBA from the State University of New York. He is a recipient of the Graham and Dodd Award from the Financial Analysts Federation.

Johannes Minho Roth

Mr. Roth is the founding director and partner at FiveT Capital Holding AG, a Pfäffikon/Switzerland-based innovative financial holdings firm with activities in quantitative tailored investment and risk management solutions for institutional investors and high net-worth individuals with sophisticated wealth management, investment and risk requirements. He has many years of experience as a CIO and portfolio manager for FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG.

Mr. Roth holds a masters degree (diploma) in economics from Hohenheim University and is a board member of Insilico Biotechnology AG, a Stuttgart/Germany-based global leader in providing solutions and software for the simulation of living cells

Dr. Elliot Goldstein

Elliot Goldstein Dr. Goldstein began his career in 1980 at Sandoz Pharmaceuticals (now Novartis) where he was responsible for clinical development of numerous programs and eventually became Vice President of Clinical Research and Development at the Sandoz Research Institute managing a 200 person department. Dr. Goldstein then moved on to SmithKline Beecham Pharmaceuticals (now GSK) where he was SVP of worldwide strategic product development. Dr. Goldstein was the Chief Executive Officer and an Executive Member of the Board of Directors of British Biotech from 1998 to 2002. Following that Dr. Goldstein was Chief Operating Officer/Chief Medical Officer at Maxigen, Inc. where he was responsible for the successful execution of all key operating functions, including process development, pharmacology/biology, molecular biology, clinical/regulatory, project management and quality assurance. He is a co-founder of Vitrua, LLC; a virtual development partner consulting firm, and is currently Chief Medical Officer of Immune Pharmaceuticals, a NASDAQ listed biotech company with a focus on personalized medicine in autoimmune disease and cancer.

Dr. Goldstein received his B.Sc. from McGill University and his MD from University Aix-Marseille II, Marseille, France.

Dr. Robert Gundel

President and CEO

Robert Gundel See bio under Management.

Dr. Neil Cashman

Chief Scientific Officer and Co-founder

Dr. Neil Cashman, CSO See bio under Management.

Warren Whitehead

Chief Financial Officer

Warren Whitehead See bio under Management.